Drug Trial Radar · NCT05326347
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
247
Actual
Start
May 31, 2022
Primary completion
Aug 26, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
Conditions
- Schizophrenia
Interventions
OPC-34712FUM/ Brexpiprazole fumarateDrug
The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The frequency of Adverse EventsTime frame: From baseline to week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hayakawa Clinic
Kure-shi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.